Skip to main content

Vitamin D

Vitamin D is a fat-soluble secosteroid hormone precursor central to calcium-phosphorus homeostasis and bone metabolism, with emerging evidence for extraskeletal effects on immune function, cancer mortality, and diabetes prevention.[1][2] The 2024 Endocrine Society guideline has substantially revised prior recommendations — notably no longer endorsing specific 25(OH)D thresholds for sufficiency / deficiency, and recommending against routine screening in most populations.[3]

For the reconstructive urologist and urogynecologist, vitamin D matters most in bowel-augmented / urinary-diversion patients (chronic acidosis + diversion-related bone demineralization), post-menopausal urogyn populations, gender-affirming surgery cohorts (hormonal axis disruption), post-bariatric patients undergoing later reconstruction, and adult congenital / spina bifida transitional urology patients with chronic immobilization.

Metabolism​

Vitamin D is obtained from cutaneous synthesis (vitamin D3 / cholecalciferol from UVB-mediated conversion of 7-dehydrocholesterol) or dietary / supplemental sources (D3 or D2 / ergocalciferol). Two hydroxylation steps follow: first in the liver to 25(OH)D (calcidiol, the circulating biomarker), then in the kidney to 1,25(OH)₂D (calcitriol, the biologically active hormone). Renal production of calcitriol is tightly regulated by PTH, calcium, phosphate, and FGF-23.[1][4] The vitamin D receptor (VDR) is expressed in most tissues, mediating transcription of hundreds of genes involved in calcium absorption, cell differentiation, proliferation, and immune modulation.[3]

Assessment of Vitamin D Status​

Serum 25(OH)D is the accepted biomarker of vitamin D status because its production is not tightly regulated and thus reflects total vitamin D exposure.[3][5] However, defining optimal levels remains controversial:

OrganizationDeficiencyInsufficiencyAdequate
National Academy of Medicine (2011)< 12 ng/mL12–20 ng/mL≥ 20 ng/mL
Endocrine Society (2011)< 20 ng/mL20–30 ng/mL≥ 30 ng/mL
Endocrine Society (2024)No longer endorses specific thresholds——

The 2024 Endocrine Society guideline no longer endorses the prior 30 ng/mL target, stating that clinical-trial evidence does not support establishing distinct 25(OH)D thresholds tied to outcome-specific benefits.[3]

Epidemiology of Deficiency​

Vitamin D deficiency is one of the most common micronutrient deficiencies in the United States. NHANES data (2001–2018) demonstrate substantial prevalence of low 25(OH)D, particularly in adults with limited sun exposure, obesity, malabsorption, and darker skin pigmentation.[6] Risk factors include obesity (adipose sequestration), malabsorption, older age (reduced cutaneous synthesis), dark skin pigmentation, limited sun exposure, and few dietary sources.[1]

Skeletal Effects​

Vitamin D's best-established role is promoting intestinal calcium absorption, critical for skeletal and mineral-ion homeostasis. Deficiency accelerates bone turnover and loss, causes rickets in children and osteomalacia in adults, and contributes to osteoporotic fractures.[2][5] Recent large RCTs have challenged the assumption that supplementation prevents fractures in the general population:

  • VITAL trial (n = 25,871; 2,000 IU/day D3 vs placebo; median 5.3 years) — no significant reduction in total fractures (HR 0.98, 95% CI 0.89–1.08), nonvertebral fractures, or hip fractures, including among those with baseline 25(OH)D < 20 ng/mL.[7]
  • D-Health trial (n = 21,315; monthly 60,000 IU) — no effect on fracture risk (HR 0.94, 0.84–1.06).[8]

These studies enrolled generally healthy, vitamin-D-replete adults and may not apply to individuals with osteoporosis, very low 25(OH)D, or malabsorption.[9][8]

Cardiovascular Disease​

Despite strong observational associations between low 25(OH)D and CVD, VITAL showed no reduction in major cardiovascular events (HR 0.97, 95% CI 0.85–1.12), including MI, stroke, heart failure, or cardiovascular death.[1][10]

Cancer​

VITAL found no significant reduction in total invasive cancer incidence (HR 0.96, 0.88–1.06). However, a promising signal emerged for cancer mortality, particularly after excluding the first 1–2 years of follow-up (HR 0.75, 0.59–0.96), suggesting a potential latency effect. Updated meta-analyses including VITAL indicate a significant reduction in cancer mortality but not incidence.[10][6]

Diabetes Prevention​

In adults with high-risk prediabetes (meeting ≥ 2 of 3 ADA criteria), vitamin D supplementation (~ 3,500 IU/day average) reduced progression to type 2 diabetes by 15%, with NNT = 17. The D2d trial provided moderate-certainty evidence supporting this benefit.[11]

Immune Function and Autoimmune Disease​

Calcitriol modulates both innate and adaptive immunity — enhancing antimicrobial defense while suppressing inflammatory responses through inhibition of NF-κB and the NLRP3 inflammasome.[12][13] Low 25(OH)D correlates with increased incidence and severity of autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and inflammatory bowel disease.[12][14] Mendelian randomization has demonstrated increased risk of multiple sclerosis in individuals with genetically lowered 25(OH)D, providing some of the strongest causal evidence for an extraskeletal effect.[15] Long-term supplementation in VITAL showed a 22% reduction in autoimmune-disease incidence in post hoc analysis.[12]

2024 Endocrine Society Guideline — Key Recommendations​

The guideline recommends empiric supplementation (without routine 25(OH)D testing) in four populations:[3][11]

  1. Children aged 1–18 years — to prevent rickets and potentially reduce respiratory infections.
  2. Adults ≥ 75 years — to lower all-cause mortality (high-certainty evidence); supplementation via fortified foods or supplements > 800 IU/day.
  3. Pregnant women — to reduce risk of preeclampsia, preterm delivery, and neonatal mortality; average trial dose ~ 2,500 IU/day (typical prenatal vitamins contain only 400–600 IU).
  4. Adults with high-risk prediabetes — to reduce progression to type 2 diabetes (NNT = 17).

For healthy adults 19–74, the guideline suggests against routine supplementation beyond the DRI (600 IU/day for ages 50–70; 800 IU/day for > 70) and against routine 25(OH)D testing.[3][11]

Treatment of Deficiency​

When deficiency is identified in patients with established indications (metabolic bone disease, malabsorption, CKD), the AACE/ACE guideline recommends vitamin D3 5,000 IU daily for 8–12 weeks to achieve 25(OH)D > 30 ng/mL, followed by maintenance of 1,000–2,000 IU daily. Higher doses may be needed in obesity or malabsorption. Cholecalciferol (D3) is preferred over ergocalciferol (D2) due to superior potency and assay accuracy.[5][16] Patients with end-stage renal or hepatic disease may require activated vitamin D (calcitriol 0.25–0.5 μg/day). In granulomatous diseases, levels > 30 ng/mL can worsen hypercalcemia, requiring careful monitoring.[16]

Toxicity​

The safe upper limit is generally considered 4,000 IU/day (NAM), though some guidelines cite 10,000 IU/day. Notably, the Calgary Vitamin D Study found that high-dose supplementation (4,000 or 10,000 IU/day for 3 years) resulted in dose-dependent bone-density loss at the radius compared with 400 IU/day, raising concerns about potential skeletal harm from supraphysiologic dosing.[17]

Reconstructive Relevance​

Vitamin D matters in reconstructive urology / urogynecology in five high-yield scenarios:

  1. Bowel-augmented bladder and urinary diversion — Chronic metabolic acidosis from urinary contact with ileum / colon drives diversion-related bone demineralization and accelerated osteopenia / osteoporosis. Routine surveillance with 25(OH)D, calcium, phosphate, PTH, and bicarbonate is standard; replete 25(OH)D before considering bisphosphonate or denosumab in established bone loss. Cross-reference: Renal Function & Metabolic Surveillance.
  2. Post-menopausal urogynecology — In the AUGS-IUGA / NAMS framework for prolapse + osteoporosis screening, 25(OH)D + DXA is the standard preoperative bone-health workup before complex reconstructive prolapse repair, and post-operative supplementation is part of broader bone-health management.
  3. Gender-affirming surgery cohorts — Hormonal-axis disruption (post-orchiectomy, GnRH-analog use, estrogen / testosterone therapy) creates differential bone-density risk; 25(OH)D repletion is part of GAS perioperative optimization, particularly before staged procedures over extended hormonal modulation.
  4. Post-bariatric patients undergoing later reconstruction — Deficiency is near-universal; routine post-bariatric and post-RYGB surveillance with target 25(OH)D ≥ 30 ng/mL is the standing convention. Patients on GLP-1 RAs may have additionally compromised intake from appetite suppression.
  5. Adult congenital / transitional urology (spina bifida, exstrophy, post-augmentation) — Chronic immobilization, augmented-bladder acidosis, and CKD progression compound to drive bone disease. Consider 25(OH)D + 1,25(OH)₂D + PTH + intact FGF-23 when CKD is significant.

For most healthy reconstructive patients without these risk factors, do not routinely test 25(OH)D per the 2024 Endocrine Society guideline — supplement empirically in the four indicated populations and otherwise focus diagnostic energy elsewhere.

See Also​

References​

1. Michos ED, Cainzos-Achirica M, Heravi AS, Appel LJ. "Vitamin D, Calcium Supplements, And Implications for Cardiovascular Health: JACC Focus Seminar." Journal of the American College of Cardiology. 2021;77(4):437–449. doi:10.1016/j.jacc.2020.09.617

2. Bouillon R, Marcocci C, Carmeliet G, et al. "Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions." Endocrine Reviews. 2019;40(4):1109–1151. doi:10.1210/er.2018-00126

3. Demay MB, Pittas AG, Bikle DD, et al. "Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline." The Journal of Clinical Endocrinology and Metabolism. 2024;109(8):1907–1947. doi:10.1210/clinem/dgae290

4. Cesareo R, Attanasio R, Caputo M, et al. "Italian Association of Clinical Endocrinologists (AME) and AACE Position Statement: Clinical Management of Vitamin D Deficiency in Adults." Nutrients. 2018;10(5):546. doi:10.3390/nu10050546

5. Khammissa RAG, Fourie J, Motswaledi MH, et al. "The Biological Activities of Vitamin D and Its Receptor in Relation to Calcium and Bone Homeostasis, Cancer, Immune and Cardiovascular Systems, Skin Biology, and Oral Health." BioMed Research International. 2018;2018:9276380. doi:10.1155/2018/9276380

6. Allen LH. "Micronutrients — Assessment, Requirements, Deficiencies, and Interventions." The New England Journal of Medicine. 2025;392(10):1006–1016. doi:10.1056/NEJMra2314150

7. LeBoff MS, Chou SH, Ratliff KA, et al. "Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults." The New England Journal of Medicine. 2022;387(4):299–309. doi:10.1056/NEJMoa2202106

8. Ye C, Ebeling P, Kline G. "Osteoporosis." Lancet. 2025;406(10514):2003–2016. doi:10.1016/S0140-6736(25)01385-6

9. LeBoff MS, Bischoff-Ferrari HA. "The Effects of Vitamin D Supplementation on Musculoskeletal Health: The VITAL and DO-Health Trials." The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023;78(Suppl 1):73–78. doi:10.1093/gerona/glad073

10. Manson JE, Bassuk SS, Buring JE. "Principal Results of the VITamin D and OmegA-3 TriaL (VITAL) and Updated Meta-Analyses of Relevant Vitamin D Trials." The Journal of Steroid Biochemistry and Molecular Biology. 2020;198:105522. doi:10.1016/j.jsbmb.2019.105522

11. Dakkak M, He A, He AM. "Vitamin D for Prevention of Disease: Guidelines From the Endocrine Society." American Family Physician. 2026;113(3):291–293.

12. Cutolo M, Smith V, Paolino S, Gotelli E. "Involvement of the Secosteroid Vitamin D in Autoimmune Rheumatic Diseases and COVID-19." Nature Reviews Rheumatology. 2023;19(5):265–287. doi:10.1038/s41584-023-00944-2

13. Liu Q, Li Z, Li S, et al. "Vitamin D3 as an Immunomodulatory Agent: Molecular Mechanisms, Clinical Translation, and Precision Therapeutic Strategies." Frontiers in Immunology. 2026;17:1770141. doi:10.3389/fimmu.2026.1770141

14. Ao T, Kikuta J, Ishii M. "The Effects of Vitamin D on Immune System and Inflammatory Diseases." Biomolecules. 2021;11(11):1624. doi:10.3390/biom11111624

15. Bouillon R, Manousaki D, Rosen C, et al. "The Health Effects of Vitamin D Supplementation: Evidence From Human Studies." Nature Reviews Endocrinology. 2022;18(2):96–110. doi:10.1038/s41574-021-00593-z

16. Camacho PM, Petak SM, Binkley N, et al. "American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2020 Update." Endocrine Practice. 2020;26(Suppl 1):1–46. doi:10.4158/GL-2020-0524SUPPL

17. Burt LA, Billington EO, Rose MS, et al. "Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial." JAMA. 2019;322(8):736–745. doi:10.1001/jama.2019.11889